» Articles » PMID: 37513715

Have Diagnostics, Therapies, and Vaccines Made the Difference in the Pandemic Evolution of COVID-19 in Comparison with "Spanish Flu"?

Overview
Journal Pathogens
Date 2023 Jul 29
PMID 37513715
Authors
Affiliations
Soon will be listed here.
Abstract

In 1918 many countries, but not Spain, were fighting World War I. Spanish press could report about the diffusion and severity of a new infection without censorship for the first-time, so that this pandemic is commonly defined as "Spanish flu", even though Spain was not its place of origin. "Spanish flu" was one of the deadliest pandemics in history and has been frequently compared with the coronavirus disease (COVID)-19 pandemic. These pandemics share similarities, being both caused by highly variable and transmissible respiratory RNA viruses, and diversity, represented by diagnostics, therapies, and especially vaccines, which were made rapidly available for COVID-19, but not for "Spanish flu". Most comparison studies have been carried out in the first period of COVID-19, when these resources were either not yet available or their use had not long started. Conversely, we wanted to analyze the role that the advanced diagnostics, anti-viral agents, including monoclonal antibodies, and innovative COVID-19 vaccines, may have had in the pandemic containment. Early diagnosis, therapies, and anti-COVID-19 vaccines have markedly reduced the pandemic severity and mortality, thus preventing the collapse of the public health services. However, their influence on the reduction of infections and re-infections, thus on the transition from pandemic to endemic condition, appears to be of minor relevance. The high viral variability of influenza and coronavirus may probably be contained by the development of universal vaccines, which are not easy to be obtained. The only effective weapon still remains the disease prevention, to be achieved with the reduction of promiscuity between the animal reservoirs of these zoonotic diseases and humans.

Citing Articles

mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases.

Brandi R, Paganelli A, DAmelio R, Giuliani P, Lista F, Salemi S Vaccines (Basel). 2025; 12(12.

PMID: 39772079 PMC: 11680146. DOI: 10.3390/vaccines12121418.


Power spectral density and similarity analysis of COVID-19 mortality waves across countries.

Manjarrez E, Delfin E, Dominguez-Nicolas S, Flores A Heliyon. 2024; 10(15):e35546.

PMID: 39170280 PMC: 11336732. DOI: 10.1016/j.heliyon.2024.e35546.


Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update.

Gambichler T, Schrama D, Kapynen R, Weyer-Fahlbusch S, Becker J, Susok L Vaccines (Basel). 2024; 12(5).

PMID: 38793784 PMC: 11125734. DOI: 10.3390/vaccines12050533.


COVID-19 post-pandemic reflections from sub-Saharan Africa: what we know now that we wish we knew then.

Oleribe O, Taylor-Robinson S, Taylor-Robinson A Public Health Pract (Oxf). 2024; 7:100486.

PMID: 38495538 PMC: 10943955. DOI: 10.1016/j.puhip.2024.100486.

References
1.
Tompa D, Immanuel A, Srikanth S, Kadhirvel S . Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. Int J Biol Macromol. 2021; 172:524-541. PMC: 8055758. DOI: 10.1016/j.ijbiomac.2021.01.076. View

2.
Luke T, Kilbane E, Jackson J, Hoffman S . Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med. 2006; 145(8):599-609. DOI: 10.7326/0003-4819-145-8-200610170-00139. View

3.
Boekel L, Hooijberg F, van Kempen Z, Vogelzang E, Tas S, Killestein J . Perspective of patients with autoimmune diseases on COVID-19 vaccination. Lancet Rheumatol. 2021; 3(4):e241-e243. PMC: 7906725. DOI: 10.1016/S2665-9913(21)00037-0. View

4.
Chien Y, Klugman K, Morens D . Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic. J Infect Dis. 2010; 202(11):1639-48. PMC: 3107550. DOI: 10.1086/657144. View

5.
Alsoussi W, Malladi S, Zhou J, Liu Z, Ying B, Kim W . SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. Nature. 2023; 617(7961):592-598. DOI: 10.1038/s41586-023-06025-4. View